drugset

drugset / Trial / NCT06716424

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

NCT06716424 ↗

Phase 4 Completed 105 enrolled Sanofi

NaSingle-groupOpen-labelOther

Summary

This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.

Timeline

Start: 2025-01-06
Primary completion: 2026-06-12
Completion: 2026-06-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	iGlarLixi	Unknown	—	Subcutaneous

Indications